Researchers at UC San Diego have discovered that the enzyme MICAL2 accelerates tumor growth in pancreatic cancer by ...

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

Pancreatic cancer is one of the most lethal malignancies, with nearly 50,000 deaths annually in the United States, according ...

The disease is rarely found in time for lifesaving treatment, and kills about half a million people annually; here is what to ...

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...

Mitazalimab is under clinical development by Alligator Bioscience and currently in Phase I for Pancreatic Cancer.

Ibrilatazar is under clinical development by Ability Pharmaceuticals and currently in Phase III for Metastatic Pancreatic Cancer.

Pancreatic cancer has a poor prognosis accounting for a 5-year overall survival rate lower than 10%. This proportion could reach about one-third of patients ...

Autonomix Medical shares were up 24% to $4.10 after the company said it received a patent from the U.S. Patent and Trademark Office.

This discovery points to a new way to tackle pancreatic cancer. If scientists can find a way to block CD9 or stop the cancer ...